Determination of the therapeutic efficacy of ginger in the treatment of migraine headaches

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220818055740N2

Enrollment

Registered

2022-09-27

Start date

2019-06-29

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: The control group received 500 mg/day Depakene orally daily once for sixteen weeks mgmanufactured by Zintoma (Gol darou Co.). Intervention 2: Intervention group: The treatment group re

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18 to 65 years; history of migraine headache before performing the study based on IHS criteria; headache from moderate to severe less than six days by visual analogue score(Vas); absence of diseases such as liver, heart, active stomach ulcer, diabetes and renal failure.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Abnormal vital signs during the study;, new abnormal findings during CT scan; dissatisfaction patients to continue the study;, and observation of drug sensitivity.

Design outcomes

Primary

Measure	Time frame
Migraine headache. Timepoint: One month after intervention. Method of measurement: VAS, PSQI, MIDAS questionnaires.	—

Secondary

Measure	Time frame
Migraine headache. Timepoint: One month after intervention. Method of measurement: VAS, PSQI, MIDAS questionnaires.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNahid Jivad

Shahre-kord University of Medical Sciences

jivad@skums.ac.ir+98 38 3335 1031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026